中国肺癌杂志2013，Vol.16Issue(6)：325-329,5.DOI:10.3779/j.issn.1009-3419.2013.06.10
贝伐珠单抗长期维持治疗晚期非小细胞肺癌39个月的病例报告及相关文献回顾
Long-term Survival of A Patient with Advanced Non-small Cell Lung Cancer on Bevacizumab Therapy: Case Report and Review of the Literature
武玮 1唐俊舫 1吴羽华 1朱允中 1徐丽艳 1史鹤玲 1孟弃逸 1刘赞 1郭丽丽1
作者信息
- 1. 101149 北京,首都医科大学附属北京胸科医院肿瘤科
- 折叠
摘要
Abstract
We report an advanced stage Chinese female lung adenocarcinoma patient who was negative for epidermal growth factor receptor (EGFR),V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) gene mutations,also negative for chinodem microtubule-associated protein-like 4/anaplastic lymphoma kinase (EML4-ALK) gene rearrangement and treated with bevacizumab (15 mg/kg) in combination with 6 cycles of conventional doses of paclitaxel and carboplatin chemotherapy.She was then treated with maintenance bevacizumab for a total of 42 cycles,the total dose of bevacizumab is 44,730 mg.The progression-free survival was 39 months.Our findings suggest that maintenance bevacizumab for the treatment of non-small cell lung cancer (NSCLC) is safe and its benefit for long-term survival overwhelms its side effects.关键词
贝伐珠单抗/化疗/肺肿瘤Key words
Bevacizumab/ Chemotherapy/ Lung neoplasms引用本文复制引用
武玮,唐俊舫,吴羽华,朱允中,徐丽艳,史鹤玲,孟弃逸,刘赞,郭丽丽..贝伐珠单抗长期维持治疗晚期非小细胞肺癌39个月的病例报告及相关文献回顾[J].中国肺癌杂志,2013,16(6):325-329,5.
